

Correction to “Feprazone Mitigates IL-1 β -Induced Cellular Senescence in Chondrocytes”

Zhusong Huang, Jinfu Lan, and Xi Gao*

ACS Omega 2021, 6 (14), 9442–9448. DOI: [10.1021/acsomega.0c06066](https://doi.org/10.1021/acsomega.0c06066)




Cite This: ACS Omega 2022, 7, 7430–7430



Read Online

ACCESS |

 Metrics & More

 Article Recommendations

The following minor errors need to be corrected:

On Page 9444, the Figure 4 legend should read: “Feprazone reduced the expressions of PAI-1 and p21 in IL-1 β -challenged C-28/I2 chondrocytes. Cells were stimulated with IL-1 β (10 ng/mL) in the presence or absence of Feprazone (20 μ M). (A) mRNAs of PAI-1 and p21 and (B) proteins of PAI-1 and p21 ($n = 5$; ###, $P < 0.001$ vs the vehicle group; &, $P < 0.05$ vs the IL-1 β group; &&, $P < 0.01$ vs the IL-1 β group)”.

On Page 9447, reference 17 should be: “Fletcher, M. R.; Loebel, W.; Scott, J. T. Feprazone, a new anti-inflammatory agent. Studies of potency and gastrointestinal tolerance. *Ann. Rheum. Dis.* 1975, 34, 190–194”.

Received: February 6, 2022

Published: February 15, 2022

